News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Policy
Neurocrine Biosciences, Inc. Delays Indiplon Application To Summer 2008
November 3, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Nov 2 (Reuters) - Neurocrine Biosciences Inc. (NBIX.O: Quote, Profile, Research) on Thursday delayed the re-submission for approval of its experimental sleep drug indiplon to summer 2008.
>>>
Discuss This Story
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
MORE ON THIS TOPIC
Alzheimer’s disease
Lilly Gets FDA Label Update for Alzheimer’s Drug To Mitigate Safety Concerns
July 9, 2025
·
2 min read
·
Annalee Armstrong
Podcast
Second Half Milestones, KalVista’s Surprise Approval, Another RFK Jr. Lawsuit, More
July 9, 2025
·
1 min read
·
Heather McKenzie
Government
Trump’s Tax Law Restores Orphan Drug Exemptions, Cuts Medicaid, Threatens 340B Program and Gives PBMs a Pass
July 8, 2025
·
3 min read
·
Tristan Manalac
Legal
Medical Groups Sue RFK Jr. Over ‘Baseless and Uninformed’ Changes to COVID-19 Vaccine Policy
July 8, 2025
·
2 min read
·
Tristan Manalac
